eli lilly sues four telehealth compounding glp-1 companies FDA issued 25 warning letters to for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of 🚨 SPECIAL REPORT: Eli Lilly

Anjana RM, Pradeepa R, Unnikrishnan R, Tiwaskar M, Aravind SR, Saboo B, Joshi SR, Mohan V

A reorganization plan is expected within 40 days, according to a statement released Tuesday

IV therapy with antioxidants can help neutralize free radicals, potentially reducing inflammation and flare-ups while supporting long-term health

Companies should identify the most influential stakeholders for their brand whether HCPs, influencers and / or digital platforms and build partnerships that enable scalable awareness and adherence

Impact of coronary lesion progression on MACEs in T2D patients Coronary lesion progression, including in-stent restenosis (ISR) and non-target lesion progression (NTLP), significantly impacts major adverse cardiovascular events (MACEs) in type 2 diabetes (T2D) patients post-PCI